ºù«Ӱҵ

All publications

Journal articles

• Puelles J, Arija P, Durno N, Pantiri K, Subramanian R, Jack K, Chambenoit O, Boeri M, van Hout B & Silverberg JI (2024) . British Journal of Dermatology, 191(Supplement_2).
• Schneider P, Devlin N, van Hout B & Brazier J (2024) . Health Economics.
• Schneider P, Blankart K, Brazier J, van Hout B & Devlin N (2024) . Value in Health, 27(3), 376-382.
• Devlin NJ, Pan T, Sculpher M, Jit M, Stolk E, Rowen D, van Hout B & Norman R (2023) . PharmacoEconomics, 41(10), 1165-1174.
• Powell PA, Karimi M, Rowen D, Devlin N, van Hout B & Brazier JE (2023) . Quality of Life Research, 32(4), 1187-1197.
• Schneider P, van Hout B, Heisen M, Brazier J & Devlin N (2022) . Wellcome Open Research, 7.
• Piena MA, Kroep S, Simons C, Fenwick E, Harty GT, Wong SL & van Hout BA (2022) . Advances in Therapy, 39(2), 892-908.
• Landmesser U, Lindgren P, Hagström E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Svensson ME, Sibartie M & Fonarow GC (2022) . European Heart Journal - Quality of Care and Clinical Outcomes, 8(1), 31-38.
• van Hout BA & Shaw JW (2021) . Value in Health, 24(9), 1285-1293.
• Bunge EM, van Hout B, Haas S, Spentzouris G & Cohen A (2021) . BMJ Open, 11(2).
• Morrone D, Kroep S, Ricci F, Renda G, Patti G, Kirchhof P, Chuang L-H, van Hout B & De Caterina R (2020) . Journal of Clinical Medicine, 9(12).
• Descamps OS, Van Hout B, Lindgren P, Villa G, Urbich M & Fonarow GC (2020) . Atherosclerosis, 315, e36-e36.
• Ray KK, Bridges I, Bruckert E, Van Hout B, Sibartie M & Villa G (2020) . European Heart Journal, 41(Supplement_2).
• Ray KK, Bruckert E, Van Hout B, Feudjo Tepie M, Bridges I & Sibartie M (2020) . European Heart Journal, 41(Supplement_2).
• Morrone D, Kroep S, Ricci F, Renda G, Patti G, Kirchhof P, Chuang LC, Van Hout B & De Caterina R (2020) . European Heart Journal, 41(Supplement_2).
• van Hout B, Hawe E & Cohen AT (2020) . TH Open, 04(03), e245-e254.
• van Hout B, Mulhern B, Feng Y, Shah K & Devlin N (2020) . Value in Health.
• Bouwmeester W, Briggs A, van Hout B, Hájek R, Gonzalez-McQuire S, Campioni M, DeCosta L & Brozova L (2019) . Oncology and Therapy, 7(2), 141-157.
• Fonarow GC, van Hout B, Villa G, Arellano J & Lindgren P (2019) . JAMA Cardiology.
• Chuang L-H, Gumbs P, van Hout B, Agnelli G, Kroep S, Monreal M, Bauersachs R, Willich SN, Gitt A, Mismetti P , Cohen A et al (2019) . Quality of Life Research.
• Chuang L-H, Cohen AT, Agnelli G, Gumbs PD, Bauersachs R, Kroep S, Gitt AK, Monreal M, Willich SN & van Hout B (2019) . Quality of Life Research, 28(5), 1155-1177.
• Stolk E, Ludwig K, Rand K, van Hout B & Ramos-Goñi JM (2019) . Value in Health, 22(1), 23-30.
• Willich SN, Chuang L-H, van Hout B, Gumbs P, Jimenez D, Kroep S, Bauersachs R, Monreal M, Agnelli G & Cohen A (2018) . Thrombosis Research, 170, 181-191.
• Chuang LH, van Hout B, Cohen AT, Gumbs PD, Kroep S, Bauersachs R, Gitt A, Monreal M, Willich SN & Agnelli G (2018) . Thrombosis Research, 170, 165-174.
• Devlin NJ, Shah KK, Mulhern BJ, Pantiri K & van Hout B (2018) . The European Journal of Health Economics.
• Feng Y, Hole A, Karimi M, Tsuchiya A & van Hout BA (2018) . Health Economics, 27(8), 1247-1263.
• Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B & Devlin N (2018) . PharmacoEconomics, 36(6), 727-727.
• Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B & Devlin N (2018) . PharmacoEconomics, 1-15.
• Devlin NJ, Shah KK, Feng Y, Mulhern B & van Hout B (2018) . Health Economics, 27(1), 7-22.
• Clay E, Jamotte A, Verhamme P, Cohen AT, Van Hout BA & Gumbs P (2018) . Journal of Market Access & Health Policy, 6(1), 1495974-1495974.
• Feng Y, Devlin N, Shah KK, Mulhern B & van hout B (2018) . Health Economics, 27(1), 23-38.
• Rowen DL, Azzabi Zouraq I, Chevrou-Severac H & van Hout B (2017) . PharmacoEconomics, 35(Suppl 1), 11-19.
• Ara RM, Peasgood T, Mukuria C, Chevrou-Severac H, Rowen D, Azzabi-Zouraq I, Paisley S, van Hout B & Brazier J (2017) . PharmacoEconomics, 35(Suppl 1), 7-9.
• Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R & Sabatine MS (2017) . JAMA Cardiology.
• Waldeck AR, Botteman MF, White RE & van Hout BA (2017) . Journal of Managed Care & Specialty Pharmacy, 23(6-a Suppl), S6-S12.
• Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F, Masana L, Bayes-Genis A & Hout BV (2017) . Clinical Therapeutics, 39(4), 771-786.e3.
• Bennison C, Stephens S, Lescrauwaet B, Van Hout B & Jackson TL (2016) . Journal of Market Access & Health Policy, 4(1).
• Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R & van Hout B (2016) . Clinical Cardiology, 39(6), 313-320.
• Begum N, Stephens S, Schoeman O, Fraschke A, Kirsch B, Briere J-B, Verheugt FWA & van Hout BA (2015) . Cardiology and Therapy, 4(2), 131-153.
• Taylor B, Lothgren M, Villa G, Lindgren P, Van Hout B & Mark D (2015) . Circulation, 132(suppl_3).
• Stephens S, Botteman MF, Cifaldi MA & van Hout BA (2015) . BMJ Open, 5(6).
• Thomas JA, Tubaro A, Barber N, Thorpe A, Armstrong N, Bachmann A & Van Hout B (2015) . Value in Health, 18(4), 376-386.
• Rowen D, Brazier J & Van Hout B (2015) . Medical Decision Making, 35(3), 328-340.
• Golicki D, Niewada M, Hout BV, Janssen MF & Pickard AS (2014) . Value in Health Regional Issues, 4, 19-23.
• Krabbe PFM, Devlin NJ, Stolk EA, Shah KK, Oppe M, van Hout B, Quik EH, Pickard AS & Xie F (2014) . Medical Care, 52(11), 935-943.
• Ara R, Kearns B, vanHout BA & Brazier JE (2014) . BMC Res Notes, 7, 438.
• Oppe M, Devlin NJ, van Hout B, Krabbe PFM & de Charro F (2014) . Value Health, 17(4), 445-453.
• Heeg BM & van Hout BA (2014) . Med Decis Making, 34(3), 300-310.
• Gu NY, Botteman MF, Gerber RA, Ji X, Postema R, Wan Y, Sianos G, Anthony I, Cappelleri JC, Szczypa P & van Hout B (2013) . Acta Orthop, 84(6), 571-578.
• Majer IM, Gueron B, Kotapati S & Van Hout B (2013) . Value in Health, 16(7), A594-A594.
• Thurston S & Van Hout B (2013) . Value in Health, 16(7), A590-A590.
• Mulhern B, Devlin N, Shah K, Feng Y & Van Hout B (2013) Developing an EQ-5D-5L value set for England. QUALITY OF LIFE RESEARCH, 22.
• Devlin N, Buckingham K, Shah K, Tsuchiya A, Tilling C, Wilkinson G & Van Hout B (2013) . Health Economics (United Kingdom), 22(5), 517-532.
• Krabbe PFM, Devlin N, Stolk E, Shah K, Oppe M, Van Hout B, Pickard S & Xie F (2012) Evidence from four countries on the validity of the discrete choice model in quantifying health-states for the new EQ-5D-5L. QUALITY OF LIFE RESEARCH, 21, 12-12.
• Gu NY, Bell C, Botteman MF, Ji X, Carter JA & van Hout B (2012) . The Patient: Patient-Centered Outcomes Research, 5(3), 185-197.
• Gu NY, Bell C, Botteman MF, Ji X, Carter JA & van Hout B (2012) . Patient, 5(3), 185-197.
• van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P & Pickard AS (2012) . Value Health, 15(5), 708-715.
• Gu NY, Botteman M, Gerber R, Ji X, Postema R, Wan W, Sianos G, Anthony I, Cappelleri JC, Szczypa P & Van Hout B (2012) . Value in Health, 15(4), A50-A50.
• Cohen DJ, Van Hout B, Serruys PW, Mohr FW, Macaya C, Den Heijer P, Vrakking MM, Wang K, Mahoney EM, Audi S , Leadley K et al (2012) . Survey of Anesthesiology, 56(1), 6-6.
• Rowen D, Mulhern B, Banerjee S, Van Hout B, Young TA, Knapp M, Smith SC, Lamping DL & Brazier JE (2012) . Value in Health, 15(2), 346-356.
• Borkent-Raven BA, Janssen MP, Van Der Poel CL, Bonsel GJ & Van Hout BA (2012) . Transfusion, 52(3), 478-488.
• Borkent-Raven BA, Janssen MP, van der Poel CL, Bonsel GJ & van Hout BA (2012) . Transfusion, 52(3), 478-488.
• Cohen DJ, Lavelle TA, Van Hout B, Li H, Lei Y, Robertus K, Pinto D, Magnuson EA, Mcgarry TF, Lucas SK , Horwitz PA et al (2012) . Catheter Cardiovasc Interv, 79(2), 198-209.
• Gu NY, Botteman MF, Ji X, Bell CF, Carter JA & van Hout B (2011) . Health Qual Life Outcomes, 9, 119.
• Cohen DJ, Van Hout B, Serruys PW, Mohr FW, Macaya C, den Heijer P, Vrakking MM, Wang K, Mahoney EM, Audi S , Leadley K et al (2011) . N Engl J Med, 364(11), 1016-1026.
• Raaijmakers MA, Posthumus JA, van Hout BA, van Engeland H & Matthys W (2011) . Prev Sci, 12(2), 192-200.
• Fischer K, Pouw ME, Lewandowski D, Janssen MP, van den Berg HM & van Hout BA (2011) . Haematologica, 96(5), 738-743.
• Van Hout BA (2011) Safe blood transfusion: How much do we want to pay?. Blood Transfusion, 9(SUPPL. 1).
• Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ & van Hout BA (2011) . Vox Sang, 100(2), 196-203.
• Gu NY, Bell C, Ji X, Carter J, Botteman M & Van Hout BA (2010) . Value in Health, 13(7), A472-A473.
• Wassenberg MWM, de Wit GA, van Hout BA & Bonten MJM (2010) . PLoS One, 5(7), e11562.
• Logman J, Heeg B, Herlitz J & Hout B (2010) Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden. Applied Health Economics and Health Policy, 8(4), 251-265.
• Logman JFS, Stephens J, Heeg B, Haider S, Cappelleri J, Nathwani D, Tice A & van Hout BA (2010) . Curr Med Res Opin, 26(7), 1565-1578.
• Thurston SJ, Heeg B, de Charro F & van Hout B (2010) . Curr Med Res Opin, 26(3), 641-651.
• Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ & van Hout BA (2010) . Vox Sang, 99(1), 54-64.
• Morice M-C, Hout BV, Berland J, Bessou J-P, Carrié D, Dawkins K, Mohr F & Serruys P (2010) . Archives of Cardiovascular Diseases Supplements, 2(1), 20-20.
• Hensen M, Heeg B, Löthgren M & van Hout B (2010) . Appl Health Econ Health Policy, 8(5), 327-341.
• Logman JFS, Heeg BMS, Herlitz J & van Hout BA (2010) . Appl Health Econ Health Policy, 8(4), 251-265.
• Logman JFS, Heeg BMS, Botteman MF, Kaura S & van Hout BA (2010) . Ann Oncol, 21(7), 1529-1536.
• Logman F, Heeg B, Botteman M, Kaura S & van Hout B (2009) . Poster Session Abstracts.
• Lieuw On MML, Heeg BMS, De Charro F & van Hout BA (2009) . Value in Health, 12(7), A235-A235.
• Janssen MP, Cator EA, van der Poel CL, Schaasberg WP, Bonsel GJ & van Hout BA (2009) . Vox Sang, 96(4), 298-308.
• Treur MJ, McCracken F, Heeg B, Joshi AV, Botteman MF, De Charro F & Van Hout B (2009) . Haemophilia, 15(2), 420-436.
• Treur M, Heeg B, Möller H-J, Schmeding A & van Hout B (2009) . BMC Health Serv Res, 9, 32.
• Borkent-Raven BA, Janssen MP, van der Poel CL, de Wit GA, Bonsel GJ & van Hout BA (2009) . Transfusion, 49(2), 311-319.
• Turpie AG, Kreutz R, Haas S & Van Hout B (2009) Clinical benefits of rivaroxaban for VTE prevention after elective hip or knee replacement surgery. EJHP Practice, 15(3), 34-36.
• Logman JFS, Heeg BMS, Botteman MF, Kaura S & van Hout BA (2008) . European Journal of Cancer Supplements, 6(7), 69-70.
• Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, de Charro F & van Hout B (2008) . Value Health, 11(7), 1007-1021.
• Logman JFS, Treur MJ, Verheggen BG, Heeg BMS, Stephens JM, Haider S, Cappelleri JC, Nathwani D, Tice A & Van Hout BA (2008) . Value in Health, 11(6), A428-A428.
• Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, Cribier A, De Jaegere P, Fournial G, Kappetein AP , Kovac J et al (2008) . EuroIntervention, 4(2), 193-199.
• Vahanian A, Alfieri OR, Al-Attar N, Antunes MJ, Bax J, Cormier B, Cribier A, De Jaegere P, Fournial G, Kappetein AP , Kovac J et al (2008) . Eur J Cardiothorac Surg, 34(1), 1-8.
• Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, Cribier A, De Jaegere P, Fournial G, Kappetein AP , Kovac J et al (2008) . Eur Heart J, 29(11), 1463-1470.
• Smulders YM, Burgers JS, Scheltens T, van Hout BA, Wiersma T, Simoons ML & Guideline development group for the Dutch guideline for multidisciplinary cardiovascular risk management (2008) Clinical practice guideline for cardiovascular risk management in the Netherlands.. Neth J Med, 66(4), 169-174.
• Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Schramm W, Van HBA , Willian AR et al (2008) Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group (vol 14, pg 127, 2008). HAEMOPHILIA, 14(2), 414-414.
• Raaijmakers M, Koffijberg H, Posthumus J, van Hout B, van Engeland H & Matthys W (2008) . Contemp Clin Trials, 29(2), 293-303.
• Hensen M, Treur MJ, Heeg BMS, Lothgren M & Van Hout B (2008) . Schizophrenia Research, 98, 73-74.
• Heeg BMS, Antunes J, Figueira ML, Jara JM, Marques Teixeira J, Palha AP, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C & Van Hout BA (2008) . Curr Med Res Opin, 24(2), 349-358.
• Heeg BMS, Damen J, Buskens E, Caleo S, de Charro F & van Hout BA (2008) . Pharmacoeconomics, 26(8), 633-648.
• Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Schramm W, van Hout BA , Willan AR et al (2008) . Haemophilia, 14(1), 127-132.
• Janssen MP, Over J, van der Poel CL, Cuijpers HTM & van Hout BA (2008) . Transfusion, 48(1), 153-162.
• Heeg B, Damen J & Hout B (2007) Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events. PharmacoEconomics, 25(12), 1063-1082.
• Treur MJ, McCracken F, Heeg B, Joshi AV, Thurston S, Verheggen B, Marc B, de Charro F & van Hout B (2007) . Blood, 110(11), 3964-3964.
• Logman JFS, Taylor MJ, Neumann K, Kutikova L, Cerri KH, Van Hout BA & Kühr T (2007) . Value in Health, 10(6), A325-A325.
• Damen J, Heeg B, Lothgren M & Van Hout BA (2007) . Value in Health, 10(6), A294-A295.
• Damen J, Heeg BMS, Lothgren M & Van Hout BA (2007) . Value in Health, 10(6), A294-A294.
• Opstelten W, van Wijck AJ, van Essen GA, Moons KG, Verheij TJ, Kalkman CJ & van Hout BA (2007) . Anesthesiology, 107(4), 678-679.
• Botteman MF, Hay JW, Luo MP, Curry AS, Wong RL & van Hout BA (2007) . Rheumatology (Oxford), 46(8), 1320-1328.
• Heeg B, Damen J & Van Hout B (2007) . Pharmacoeconomics, 25(12), 1063-1082.
• Heeg BMS, Peters RJG, Botteman M & van Hout BA (2007) . Pharmacoeconomics, 25(9), 769-782.
• Ong ATL, Daemen J, van Hout BA, Lemos PA, Bosch JL, van Domburg RT & Serruys PW (2006) . Eur Heart J, 27(24), 2996-3003.
• Heeg B, van Gestel A, Hout BV, Olsen J & Haghfelt TH (2006) [Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].. Ugeskr Laeger, 168(35), 2911-2915.
• Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ & van Hout BA (2006) . Transfusion, 46(6), 956-965.
• Buskens E, Meijboom MJ, Kooijman H & Van Hout BA (2006) The use of a surgical sealant (CoSeal) in cardiac and vascular reconstructive surgery: an economic analysis.. J Cardiovasc Surg (Torino), 47(2), 161-170.
• Heeg B, Van Gestel A, Van Hout B, Olsen J & Haghfelt TH (2006) Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark. Ugeskrift for Laeger, 168(35), 2911-2915.
• Van Hout B & Pharmerit BV (2005) . Value in Health, 8(6), A116-A116.
• Van Hout B & Pharmerit BV (2005) . Value in Health, 8(6), A116-A116.
• Moller HJ, Laux G, Naber D, Gastpar MT, Klosterkotter J, Schmauss M, Heeg B, Van Gestel A, Van Hout B & Mehnert A (2005) Costs and effects of long-acting risperidone in comparison to oral atypical and conventional depot formulations for the treatment of patients with schizophrenia in Germany. PSYCHOPHARMAKOTHERAP, 12(5), 183-192.
• Al MJ, Feenstra TL & van Hout BA (2005) . HEALTH ECON, 14(7), 655-667.
• van Hout BA, Serruys PW, Lemos PA, van den Brand MJBM, van Es G-A, Lindeboom WK & Morice M-C (2005) . Heart, 91(4), 507-512.
• Hak E, Buskens E, van Essen GA, de Bakker DH, Grobbee DE, Tacken MAJB, van Hout BA & Verheij TJM (2005) . Arch Intern Med, 165(3), 274-280.
• Möller HJ, Laux G, Naber D, Gastpar MT, Klosterkötter J, Schmauss M, Heeg B, Van Gestel A, Van Hout B & Mehnert A (2005) Costs and effects of long-acting risperidone in comparison to oral atypical and conventional depot formulations for the treatment of patients with schizophrenia in Germany. Psychopharmakotherapie, 12(5), 183-192.
• Laux G, Heeg B, van Hout BA & Mehnert A (2005) . Pharmacoeconomics, 23 Suppl 1, 49-61.
• Chue PS, Heeg B, Buskens E & van Hout BA (2005) . Pharmacoeconomics, 23 Suppl 1, 62-74.
• Heeg B, Buskens E, Knapp M, van Aalst G, Dries PJT, de Haan L & van Hout BA (2005) . Pharmacoeconomics, 23 Suppl 1, 17-33.
• Clermont G, Kaplan V, Moreno R, Vincent JL, Linde-Zwirble WT, Van Hout B & Angus DC (2004) . INTENS CARE MED, 30(12), 2237-2244.
• Serruys PW, Lemos PA, van Hout BA & Arterial Revascularisation Therapies Study part II Steering Committee and Investigators (2004) . Heart, 90(9), 995-998.
• van Gestel A, Bakker J, Veraart CPWM & van Hout BA (2004) . Crit Care, 8(4), R153-R162.
• Bakker J, Levi M, van Hout BA & van Gestel A (2004) [Sepsis, a complicated syndrome with major medical and social consequences].. Ned Tijdschr Geneeskd, 148(20), 975-978.
• Legrand VMG, Serruys PW, Unger F, van Hout BA, Vrolix MCM, Fransen GMP, Nielsen TT, Paulsen PK, Gomes RS, de Queiroz e Melo JMG , Neves JPMDS et al (2004) . Circulation, 109(9), 1114-1120.
• Bakker J, Levi M, Van Hout BA & Van Gestel A (2004) Sepsis, a complicated syndrome with major medical and social consequences. Nederlands Tijdschrift voor Geneeskunde, 148(20), 975-978.
• Heeg BM, Emmermann A, Laux G, Möller HJ, Naber D & Van Hout BA (2003) . Value in Health, 6(6), 691-692.
• van Hout BA, Minjoulat-Rey MC, Quinlan D, Theeuwes A & Gabriel S (2003) Cost-effectiveness of extending prophylaxis with fondaparinux in preventing venous thromboembolism following hip fracture surgery. VALUE HEALTH, 6(6), 652-652.
• van Hout BA, Tangelder MJD, Bervoets P & Gabriel S (2003) Cost-effectiveness analysis of antithrombotic treatment with clopidogrel in patients with myocardial infarction, stroke, and peripheral arterial disease in the Netherlands. VALUE HEALTH, 6(6), 653-653.
• Maliwa MA, van der Heijden GJMG, Bots ML, van Hout BA, Casselman FP, van Swieten H & Vermeulen FEE (2003) . Cardiovasc Surg, 11(5), 381-387.
• Van Hout B, Gagnon D & Guastalla J-P (2003) . European Journal of Cancer Supplements, 1(5), S313-S314.
• Klok RM, Postma MJ, van Hout BA & Brouwers JRBJ (2003) . Aliment Pharmacol Ther, 17(10), 1237-1245.
• Hak E, van Loon S, Buskens E, van Essen GA, de Bakker D, Tacken MAJB, van Hout BA, Grobbee DE & Verheij TJM (2003) . Vaccine, 21(15), 1719-1724.
• van Hout BA, Klok RM, Brouwers JRBJ & Postma MJ (2003) . Clin Ther, 25(2), 635-646.
• Serruys PW, IJsselmuiden S, Hout BV, Vermeersch P, Bramucci E, Legrand V, Pieper M, Antoniucci D, Gomes RS, Macaya C , Boekstegers P et al (2003) . Int J Cardiovasc Intervent, 5(1), 17-26.
• Martin SC, Gagnon DD, Zhang L, Bokemeyer C, Van Marwijk Kooy M & van Hout B (2003) . Pharmacoeconomics, 21(16), 1153-1169.
• Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre P-F, Vincent J-L, Bernard G, van Hout B & PROWESS Investigators (2003) . Crit Care Med, 31(1), 1-11.
• Bonneux LGA, van Hout BA, van Delden JJM & Grobbee DE (2003) . Eur J Epidemiol, 18(12), 1107-1108.
• van Hout BA (2003) . Scand J Gastroenterol Suppl(239), 3-10.
• van Hout BA, Gagnon DD, McNulty P & O'Hagan A (2003) . Pharmacoeconomics, 21(5), 315-326.
• Van Gestel A, Bakker J, Veraart C & Van Hout B (2002) . Value in Health, 5(6), 558-558.
• Buskens E, Wermer M, van der Schaaf I, van Hout B, Bossuyt P & Rinkel G (2002) Screening for aneurysms after successful treatment for subarachnoid haemorrhage: Do we have the evidence?. VALUE HEALTH, 5(6), 493-494.
• Fischer K, van Hout BA, van der Bom JG, Grobbee DE & van den Berg HM (2002) . Acta Radiologica, 43(5), 528-532.
• Fischer K, van Hout BA, van der Bom JG, Grobbee DE & van den Berg HM (2002) Association between joint bleeds and Pettersson scores in severe haemophilia.. Acta Radiol, 43(5), 528-532.
• ten Berg JM, Kelder JC, Plokker THW & van Hout BA (2002) . Pharmacoeconomics, 20(12), 847-853.
• Beutels P, Edmunds WJ, Antoñanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E , Péchevis M et al (2002) . Pharmacoeconomics, 20(1), 1-7.
• Fischer K, Van Hout BA & Van den Berg M (2001) Prophylaxis or on-demand? The costs and effects of treatment strategies including switches.. BLOOD, 98(11), 428A-429A.
• Gagnon DD, Martin SC & van Hout B (2001) . Value in Health, 4(2), 85-85.
• Zwart-van Rijkom JE & van Hout BA (2001) . Eur Heart J, 22(16), 1476-1484.
• Oostenbrink JB, Tangelder MJ, Busschbach JJ, van Hout BA, Buskens E, Algra A, Lawson JA, Eikelboom BC & Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group (2001) . J Vasc Surg, 34(2), 254-262.
• Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG , Sousa JE et al (2001) . Circulation, 104(5), 533-538.
• van Hout BA & Simoons ML (2001) . Eur Heart J, 22(9), 751-761.
• Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schönberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA , Morel MA et al (2001) . N Engl J Med, 344(15), 1117-1124.
• Gorter JW, Oostenbrink JB, Tangelder MJD, Algra A, Buskens E, Eikelboom BC, Van Hout BA, Van Gijn J, Kappelle LJ, Koudstaal PJ , Lawson JA et al (2001) . Thrombosis and Haemostasis, 85(1), 52-56.
• Moerman CJ, Van Hout BA, Bonneux L & Witteman JCM (2001) Small health benefit can be achieved with preventative postmenopausal hormone therapy in Dutch women. Nederlands Tijdschrift voor Geneeskunde, 145(19), 910-914.
• Stooker T, van Acht JW, van Barneveld EM, van Vliet RC, van Hout BA, Hessing DJ & Busschbach JJ (2001) . Inquiry, 38(1), 73-80.
• Serruys PW, de Bruyne B, Carlier S, Sousa JE, Piek J, Muramatsu T, Vrints C, Probst P, Seabra-Gomes R, Simpson I , Voudris V et al (2000) . Circulation, 102(24), 2930-2937.
• Lindeboom WK, Disco CM, Unger F, Legrand V, Limet R, Van Herwerden L, Carere R, Lichtenstein S & Van Hout BA (2000) Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in patients with multivessel disease by age. CIRCULATION, 102(18), 549-549.
• Lindeboom WK, Unger F, Schuler G, Mohr FW, Roose PC, Van Geldorp TR, Morel MA, Disco CM & Van Hout BA (2000) Quality of life after CABG and stented angioplasty: Results from the ARTS study. CIRCULATION, 102(18), 549-549.
• Al MJ & Van Hout BA (2000) A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty.. Health Econ, 9(7), 599-609.
• Lindeboom WK, van Hout BA, Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier JJRM, Schoenberger JPAM, Buller N & Bonser R (2000) Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in diabetic patients with multi vessel disease. EUR HEART J, 21, 222-222.
• Moerman CJ, Van Hout BA, Bonneux L & Witteman JC (2000) . J Intern Med, 248(2), 143-150.
• Brouwer W, van Hout B & Rutten F (2000) . J Health Serv Res Policy, 5(2), 114-118.
• van Os N, Niessen LW, Bilo HJ, Casparie AF & van Hout BA (2000) . Health Policy, 51(3), 135-147.
• van Buuren HR, Groeneweg M, Vleggaar FP, Lesterhuis W, van Tilburg AJP, Hop WCJ, Pieterman H, Schalm SW, van Hout BA & Lameris JS (2000) The results of a randomized controlled trial evaluating TIPS and endoscopic therapy in cirrhotic patients with gastro-esophageal variceal bleeding. J HEPATOL, 32, 71-71.
• van Buuren HR, Groeneweg M, Vleggaar FP, Lesterhuis W, van Tilburg AJP, Hop WCJ, Pieterman H, Schalm SW & van Hout BA (1999) . European Journal of Gastroenterology & Hepatology, 11(12), A86-A86.
• Serruys PW, Unger F, van Hout BA, van den Brand MJ, van Herwerden LA, van Es GA, Bonnier JJ, Simon R, Cremer J, Colombo A , Santoli C et al (1999) . Semin Interv Cardiol, 4(4), 209-219.
• Busschbach JJ, McDonnell J, Essink-Bot ML & van Hout BA (1999) . J Health Econ, 18(5), 551-571.
• van Hout BA, Goes ES, Grijseels EW & van Ufford MA (1999) . Prog Cardiovasc Dis, 42(2), 167-173.
• Groener MG, van Ineveld BM, Byttebier G, van Hout BA & Rutten FF (1999) . Anticancer Drugs, 10(3), 283-288.
• van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA & Vinks AA (1999) . Ther Drug Monit, 21(1), 63-73.
• Serruys PW, Unger F, Van Hout BA, Van den Brand MJB, Van Herwerden LA, Van Es GA, Morel MA, Bonnier JJRM, Colombo A, Morice MC , Simon R et al (1999) . International Journal of Cardiovascular Interventions, 2(1), 41-50.
• De Laet CE, van Hout BA, Burger H, Weel AE, Hofman A & Pols HA (1999) . Osteoporos Int, 10(1), 66-72.
• van Hout BA (1998) . Health Econ, 7(7), 581-594.
• Brouwer W & van Hout B (1998) How should different life expectancies be valued? Diminishing marginal utility and discounting future effects have similar consequences.. BMJ, 317(7166), 1155.
• De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A & Pols HA (1998) . J Bone Miner Res, 13(10), 1587-1593.
• van Hout BA, Goes ES, Grijseels EW & Quarles van Ufford MA (1998) [Economic evaluation of cardiology; background and application].. Ned Tijdschr Geneeskd, 142(38), 2083-2086.
• Casparie AF, van Hout BA & Simoons ML (1998) [Guidelines and costs].. Ned Tijdschr Geneeskd, 142(38), 2075-2077.
• van Hout B (1998) Determining costs and cost-effectiveness of epilepsy.. Am J Manag Care, 4(9 Suppl), S501-S509.
• Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der Giessen W, Colombo A, Seabra-Gomes R , Kiemeneij F et al (1998) . Lancet, 352(9129), 673-681.
• Al MJ, van Hout BA, Michel BC & Rutten FF (1998) . Health Econ, 7(4), 327-335.
• van Hout BA, Bowman L, Zelinger DJ & Simoons ML (1998) Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.. Eur Heart J, 19 Suppl D, D59-D66.
• van Hout BA, Bowman L, Zelinger DJ & Simoons ML (1998) . Am Heart J, 135(4), S98-106.
• Chronos N, Vahanian A, Betriu A, Emanuelsson H, Goldberg S, Gulba D & van Hout BA (1998) Use of abciximab in interventional cardiology.. Eur Heart J, 19 Suppl D, D31-D39.
• Chronos N, Vahanian A, Betriu A, Emanuelsson H, Goldberg S, Gulba D & van Hout BA (1998) . Am Heart J, 135(4), S67-S76.
• van Hout BA, Cohen DJ, Koens BAH & Serruys PW (1998) . Journal of the American College of Cardiology, 31, 50-50.
• Naaborg R, Van Hout BA, Goes ES & Grijseels EWM (1998) Economic evaluation within cardiology; Background and application [4] (multiple letters). Nederlands Tijdschrift voor Geneeskunde, 142(39), 2164-2165.
• Van Hout BA, Goes ES, Grijseels EWM & Quarles Van Ufford MA (1998) Economic evaluation in cardiology; background and application. Nederlands Tijdschrift voor Geneeskunde, 142(38), 2083-2086.
• Casparie AF, Van Hout BA & Simoons ML (1998) Guidelines and costs. Nederlands Tijdschrift voor Geneeskunde, 142(38), 2075-2077.
• Benson T, Brouwer W & Van Hout B (1998) . BMJ, 317(7166), 1155.
• Barendregt JJ, Van Oortmarssen GJ, Van Hout BA, Van Den Bosch JM & Bonneux L (1998) . Math Popul Stud, 7(1), 29-109.
• van Hout BA, Simeon GP, McDonnell J & Mann JF (1997) Economic evaluation of benazepril in chronic renal insufficiency.. Kidney Int Suppl, 63, S159-S162.
• van Hout B, Gagnon D, Souêtre E, Ried S, Remy C, Baker G, Genton P, Vespignani H & McNulty P (1997) . Epilepsia, 38(11), 1221-1226.
• van der Riet AA, van Hout BA & Rutten FF (1997) . J Med Genet, 34(9), 741-745.
• De Laet CE, van Hout BA, Burger H, Hofman A & Pols HA (1997) . BMJ, 315(7102), 221-225.
• Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T & Vray M (1997) . Health Econ, 6(3), 217-227.
• Baker GA, Nashef L & van Hout BA (1997) . Epilepsia, 38 Suppl 1, S1-S8.
• VandenBergh MFQ, Kluytmans JAJW, van Hout BA, Maat APWM, Seerden RJ, McDonnel J & Verbrugh HA (1996) . Infection Control & Hospital Epidemiology, 17(12), 786-792.
• Van Hout BA, van der Woude T, de Jaegere PP, van den Brand M, van Es GA, Serruys PW & Morel MA (1996) Cost effectiveness of stent implantation versus PTCA: the BENESTENT experience.. Semin Interv Cardiol, 1(4), 263-268.
• Michel BC, van Staveren RJ, Geven WB & van Hout BA (1996) . J Health Serv Res Policy, 1(4), 198-204.
• de Laet CE, van Hout BA, Hofman A & Pols HA (1996) [Costs due to osteoporosis-induced fractures in The Netherlands; possibilities for cost control].. Ned Tijdschr Geneeskd, 140(33), 1684-1688.
• Michel BC, Al MJ, Remme WJ, Kingma JH, Kragten JA, van Nieuwenhuizen R & van Hout BA (1996) . Eur Heart J, 17(5), 731-740.
• De Laet CEDH, Burger H, van Daele PLA, van Hout B, Hofman A & Pols HAP (1996) . Osteoporosis International, 6(S1), 124-124.
• De Laet CEDH, Burger H, van Daele PLA, Pols HAP, Hofman A & van Hout B (1996) . Osteoporosis International, 6(S1), 124-124.
• De Laet CEDH, Van Hout BA, Hofman A & Pols HAP (1996) Costs of osteoporosis-related fractures in the Netherlands, 1993; possibilities of cost control. Nederlands Tijdschrift voor Geneeskunde, 140(33), 1684-1688.
• De Boer MJ, Van Hout BA, Simoons ML & Zijlstra F (1996) Cost benefit analysis of the Zwolle Infarction Study. Hart Bulletin, 27(4), 119-123.
• VandenBergh MF, Kluytmans JA, van Hout BA, Maat AP, Seerden RJ, McDonnel J & Verbrugh HA (1996) . Infect Control Hosp Epidemiol, 17(12), 786-792.
• van Hout BA & Simoons ML (1995) . Eur Heart J, 16 Suppl L, 81-85.
• de Boer MJ, van Hout BA, Liem AL, Suryapranata H, Hoorntje JC & Zijlstra F (1995) . Am J Cardiol, 76(11), 830-833.
• van Bergen PF, Jonker JJ, van Hout BA, van Domburg RT, Deckers JW, Azar AJ & Hofman A (1995) . JAMA, 273(12), 925-928.
• Michel BC & van Hout BA (1994) [Is the use of helicopters with a trauma team in severely injured accident victims in The Netherlands cost effective? A modelling approach].. Ned Tijdschr Geneeskd, 138(46), 2310-2315.
• Michel BC, Van Hout BA & Bonsel GJ (1994) . Baillieres Clin Gastroenterol, 8(3), 411-423.
• van Hout BA, Al MJ, Gordon GS & Rutten FF (1994) . Health Econ, 3(5), 309-319.
• Rutten FFH & Van Hout BA (1994) Economic evaluation and the reimbursement of drugs: Current policies and future trends. European Journal of Clinical Research, 6, 186-194.
• Michel BC & Van Hout BA (1994) Is use of helicopters with medical crews for seriously injured accident victims cost-effective in the Netherlands? A modelling approach. Nederlands Tijdschrift voor Geneeskunde, 138(46), 2310-2315.
• van Hout BA, Birnie E, Redekop WK, Lorijn RH, Bossuyt PM & Rutten FF (1994) Cost-effectiveness of HA-1A treatment for patients with sepsis.. Prog Clin Biol Res, 388, 435-443.
• van Hout BA, Wielink G, Bonsel GJ & Rutten FF (1993) . Pharmacoeconomics, 3(5), 387-397.
• van Hout B, Bonsel G, Habbema D, van der Maas P & de Charro F (1993) . J Health Econ, 12(1), 73-93.
• Van Hout BA, Rutten FF & Lorijn RH (1993) [Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome].. Ned Tijdschr Geneeskd, 137(7), 360-364.
• Van Hout BA, Rutten FFH & Lorijn RHW (1993) Cost-effectiveness of treatment of patients with sepsis with HA-IA. Nederlands Tijdschrift voor Geneeskunde, 137(7), 360-364.
• BUXTON M, OHANLON M, RUSHBY J, PEKURINEN M, SINTONEN H, BONSEL G, ESSINKBOT ML, VANHOUT B, BJORK S, LINDGREN B , PERSSON U et al (1992) EUROQOL(C) - A REPLY AND REMINDER. HEALTH POLICY, 20(3), 329-332.
• Monreal M, Agnelli G, Chuang LH, Cohen AT, Gumbs PD, Bauersachs R, Mismetti P, Gitt AK, Kroep S, Willich SN & Van Hout B () . Clinical and Applied Thrombosis/Hemostasis, 25.

Chapters

• Oppe M, Norman R, Yang Z & van Hout B (2022) , Value Sets for EQ-5D-5L (pp. 29-54). Springer International Publishing
• van Hout B & McDonnell J (2005) , EQ-5D concepts and methods: A developmental history (pp. 157-170). Springer Netherlands
• de Charro F, Busschbach J, Essink-Bot M-L, van Hout B & Krabbe P (2005) , EQ-5D concepts and methods: A developmental history (pp. 171-179). Springer Netherlands
• van Hout BA & Angus DC (2003) , Surviving Intensive Care (pp. 221-234). Springer Berlin Heidelberg

Conference proceedings papers

• Verburg-Baltussen L, Dunnewind N, Kroep S, Hout BV, Boing E & Keen R (2023) RELATIONSHIPS BETWEEN HETEROTOPIC OSSIFICATION VOLUME AND FUNCTIONAL AND QUALITY OF LIFE ENDPOINTS IN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP). VALUE IN HEALTH, Vol. 26(6) (pp S28-S29)
• Shaw J, Bennett B, Russell J, Van HBA, Norman R, Frampton K, Moreno-Koehler A, Taylor F & Cocks K (2023) THE IMPACTS OF AGE AND GENDER ON MAPPED EQ-5D5L UTILITIES AND QUALITY-ADJUSTED LIFE YEARS (QALYS) IN CANCER CLINICAL TRIALS. VALUE IN HEALTH, Vol. 26(6) (pp S334-S334)
• Shaw J, Bennett B, Khan I, Van Hout BA, Bryning S, Fox A & Hirst A (2023) COMPARING ALGORITHMS FOR MAPPING FROM EQ-5D-3L TO EQ-5D-5L IN TWO PATIENT COHORTS. VALUE IN HEALTH, Vol. 26(6) (pp S343-S344)
• Verburg-Baltussen L, Gittfried A, Kroep S, Hout BV, Boing E & Keen R (2023) RELATING HETEROTOPIC OSSIFICATION VOLUME TO JOINT FUNCTION AND QUALITY OF LIFE: A SIMULATION STUDY IN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP). VALUE IN HEALTH, Vol. 26(6) (pp S288-S288)
• Malottki K, Lawson R, Beecroft S, Van Hout BA, Heaton D, Starita C & Patel S (2022) . Value in Health, Vol. 25(12) (pp S448-S448)
• Durno N, Heisen M, Penton H, Schmid R, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T, San José Cáceres A , Mühlbacher AC et al (2022) . Value in Health, Vol. 25(12) (pp S444-S444)
• Schneider P, Brazier JE, Van Hout BA & Devlin N (2022) . Value in Health, Vol. 25(12) (pp S423-S423)
• Schneider P, Brazier JE, Devlin N & van Hout B (2022) . Value in Health, Vol. 25(7) (pp S546-S546)
• Schneider P, Brazier J, Devlin N & Hout BV (2022) . Abstracts
• Schneider P, Brazier JE, Devlin N & van Hout B (2022) THE OPUF TOOL: A NEW TYPE OF ONLINE SURVEY FOR CREATING VALUE SETS FOR THE EQ-5D-5L ON THE SOCIETAL-, GROUP-, AND INDIVIDUAL PERSON LEVEL. VALUE IN HEALTH, Vol. 25(7) (pp S546-S546)
• Schneider P, Van Hout B, Heisen M, Brazier J & Devlin N (2022) A NEW ONLINE TOOL FOR VALUING HEALTH STATES: ELICITING PERSONAL UTILITY FUNCTIONS FOR THE EQ-5D-5L. VALUE IN HEALTH, Vol. 25(1) (pp S13-S13)
• Schneider P, Brazier J, van Hout B & Devlin N (2022) Online Elicitation of Personal Utility Functions (OPUF): An Open, Modular Health Valuation Platform. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, Vol. 15(6) (pp 734-734)
• Schneider P, Brazier J, van Hout B & Devlin N (2022) The Online elicitation of Personal Utility Functions (OPUF) Tool: a new method to construct (patient) preferences for small groups and on the individual level. QUALITY OF LIFE RESEARCH, Vol. 31 (pp S9-S10)
• Schneider P, Brazier JE, Van Hout BA & Devlin N (2022) ONLINE ELICITATION OF PERSONAL UTILITY FUNCTIONS (OPUF) AN OPEN, MODULAR HEALTH VALUATION PLATFORM. VALUE IN HEALTH, Vol. 25(12) (pp S423-S423)
• Durno N, Heisen M, Penton H, Schmid R, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T, San Jose Caceres A , Muhlbacher AC et al (2022) VALUE-BASED ASSESSMENT OF CLINICAL TRIAL OUTCOMES: A HYPOTHETICAL EXAMPLE USING THE CHILDHOOD AUTISM RATING SCALE IN AUTISM SPECTRUM DISORDER. VALUE IN HEALTH, Vol. 25(12) (pp S444-S444)
• Malottki K, Lawson R, Beecroft S, Van Hout BA, Heaton D, Starita C & Patel S (2022) USING LINKED DATABASES TO EXPLORE RESOURCE USE AND REAL-WORLD OUTCOMES IN A RARE DISEASE: POMPE DISEASE IN ENGLAND. VALUE IN HEALTH, Vol. 25(12) (pp S448-S448)
• Hartl K, Durno N, Schmid R, Heisen M, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T, San Jose Caceres A , Muehlbacher A et al (2021) Preference Study in Childhood Autism Spectrum Disorder (ASD) using the Childhood Autism Rating Scale (CARS2): A Feasibility Assessment. QUALITY OF LIFE RESEARCH, Vol. 30(SUPPL 1) (pp S113-S114)
• Schneider P, Van Hout B & Brazier J (2020) FAIR INTERPERSONAL UTILITY COMPARISON IN THE CONTEXT OF HEALTH VALUATION: DESCRIPTION AND FIRST EMPIRICAL EVALUATION OF A NEW MULTI-STEP PREFERENCE AGGREGATION PROCEDURE. MEDICAL DECISION MAKING, Vol. 40(5) (pp E407-E408)
• Morrone D, Ricci F, Giulia R, Patti G, Kirchhof P, Kroep S, Chuang L-H, Van Hout B & De Caterina R (2020) Additive predictive power of the cha2ds2-vasc and has-bled scores for mortality in patients with atrial fibrillation. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 22(N) (pp N10-N10)
• Lindgren P, Hagström E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Sibartie M & Fonarow GC (2019) . Value in Health, Vol. 22 (pp S548-S548)
• Lindgren P, Hagstrom E, Van Hout B, Villa G, Urbich M, Sandelin R, Eriksson Svensson M & Fonarow GC (2019) . European Heart Journal, Vol. 40(Supplement_1)
• Ray KK, Schoonen M, Annemans L, Van Hout BA, Sibartie M, Bridges I & Bruckert E (2019) . European Heart Journal, Vol. 40(Supplement_1)
• Diakite I, Lin VW, Klijn S, Navale L, Purdum AG, Fenwick E, Botteman M & van Hout B (2019) . HemaSphere, Vol. 3 (pp 817-817)
• Fonarow GC, van Hout B, Villa G, Arellano J & Lindgren P (2019) . Journal of Clinical Lipidology, Vol. 13(3) (pp e31-e31)
• Diakite I, Lin VW, Klijn S, Navale L, Purdum AG, Fenwick E, Botteman M & van Hout B (2019) . Value in Health, Vol. 22 (pp S41-S41)
• Morrone D, Ricci F, Renda G, Patti G, Kirchhof P, Kroep S, Chuang L-H, Van Hout B & De Caterina R (2019) Additive predictive power of the CHA2DS2-VASc and has bled scores for mortality in patients with atrial fibrillation. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 21(J) (pp J23-J23)
• Ray KK, Schoonen M, Annemans L, Van Hout BA, Sibartie M, Bridges I & Bruckert E (2019) Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice. EUROPEAN HEART JOURNAL, Vol. 40 (pp 263-263)
• Lindgren P, Hagstrom E, Van Hout B, Villa G, Urbich M, Sandelin R, Svensson ME & Fonarow GC (2019) Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden. EUROPEAN HEART JOURNAL, Vol. 40 (pp 681-681)
• Lindgren P, Hagstrom E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Sibartie M & Fonarow GC (2019) COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN. VALUE IN HEALTH, Vol. 22 (pp S548-S548)
• Ray K, Bruckert E, Annemans L, Van Hout B, Schoonen M & Bridges I (2018) . European Heart Journal, Vol. 39(suppl_1)
• Kroep S, Chuang L-H, Cohen A, Gumbs P, van Hout B, Monreal M, Willich SN, Gitt A, Bauersachs R & Agnelli G (2018) . Journal of Thrombosis and Thrombolysis, Vol. 46(4) (pp 507-515)
• Kroep S, Chuang L, van Hout B, Agnelli G, Gumbs PD, Gitt AK, Monreal M, Bauersachs R, Mismetti P, Willich SN & Cohen AT (2017) . Value in Health, Vol. 20(9) (pp A601-A601)
• Chuang L, Cohen AT, Agnelli G, Gumbs PD, Bauersachs R, Kroep S, Mismetti P, Gitt AK, Monreal M, Willich SN & van Hout B (2017) . Value in Health, Vol. 20(9) (pp A623-A623)
• Chuang L, van Hout B, Cohen AT, Gumbs PD, Kroep S, Monreal M, Willich SN & Agnelli G (2017) . Value in Health, Vol. 20(9) (pp A612-A612)
• Danese M, Villa G, Taylor B, Lindgren P, Van Hout B & Lothgren M (2017) . Journal of the American College of Cardiology, Vol. 69(11) (pp 1852-1852)
• Monreal M, Agnelli G, Chuang L, Cohen AT, Gumbs PD, Bauersachs R, Mismetti P, Gitt AK, Kroep S, Willich SN & van Hout B (2017) BURDEN OF ILLNESS OF DEEP VEIN THROMBOSIS IN EUROPE - MORTALITY AND HEALTH RELATED QUALITY OF LIFE. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611)
• Chuang L, Gumbs PD, van Hout B, Agnelli G, Cohen AT, Bauersachs R, Mismetti P, Gitt AK, Kroep S, Monreal M , Willich SN et al (2017) BURDEN OF ILLNESS OF PULMONARY EMBOLISM IN EUROPE - MORTALITY AND HEALTH RELATED QUALITY OF LIFE. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611)
• Willich SN, Chuang L, van Hout B, Agnelli G, Gumbs PD, Bauersachs R, Mismetti P, Jimenez D, Gitt AK, Kroep S , Monreal M et al (2017) BURDEN OF ILLNESS OF PULMONARY EMBOLISM IN EUROPE - HEALTHCARE RESOURCE UTILIZATION AND PRODUCTIVITY LOSS. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611)
• Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F, Masana L, Bayes-Genis A & van Hout B (2016) . Value in Health, Vol. 19(7) (pp A651-A652)
• Gumbs PD, Ling-Hsiang Chuang L, Cohen AT, Agnelli G, Willich SN, Monreal M, Jimenez D & van Hout B (2016) . Value in Health, Vol. 19(7) (pp A365-A365)
• Clay E, Jamotte A, Cohen AT, van Hout B, Gumbs PD & Verhamme P (2016) . Value in Health, Vol. 19(7) (pp A653-A654)
• van Hout B, Gumbs PD, Cohen AT & Verhamme P (2016) . Value in Health, Vol. 19(7) (pp A637-A638)
• Pantiri K, Shah K, Devlin N, Mulhern B & van Hout B (2016) . Value in Health, Vol. 19(7) (pp A473-A473)
• Stapelkamp C, Byrne B & van Hout B (2016) . Value in Health, Vol. 19(7) (pp A394-A394)
• Gandra SR, Villa G, Fonarow G, Lothgren M, Lindgren P, Somaratne R & van Hout B (2016) . Value in Health, Vol. 19(3) (pp A3-A3)
• Shah K, Devlin N, Mulhern B & van Hout B (2015) . Value in Health, Vol. 18(3) (pp A37-A37)
• Villa G, Lothgren M, Gandra SR, Lindgren P & van Hout B (2014) . Value in Health, Vol. 17(7) (pp A558-A558)
• Thomas JA, Tubaro A, Barber N, Thorpe A, Armstrong N, Bachmann A & Van Hout B (2014) . European Urology Supplements, Vol. 13(1) (pp e129-e129)
• Begum N, Van Hout B, Thurston S, Schoeman O, Fraschke A & Verheugt FWA (2013) . Value in Health, Vol. 16(7) (pp A524-A524)
• Krabbe PFM, Devlin NJ, Stolk EA, Shah KK, Oppe M, van Hout B, Quik EH, Pickard AS & Xie F (2013) . VALUE IN HEALTH, Vol. 16(7) (pp A326-A326)
• Chuang LH, Treur M, Heeg B, Van Hout B & Filonenko A (2013) . Value Health, Vol. 16(3) (pp A30). United States
• Solem CT, Niederman MS, Chastre J, Wan Y, Gao X, Myers DE, Haider S, Chambers R, Li JZ, Van Hout BA & Stephens JM (2012) . VALUE IN HEALTH, Vol. 15(4) (pp A10-A10)
• Van Hout BA & Oppe M (2011) . VALUE IN HEALTH, Vol. 14(7) (pp A238-A239)
• Van Hout BA & Stevens JW (2011) . VALUE IN HEALTH, Vol. 14(7) (pp A235-A235)
• Treur M, Houwing NS, Heeg B, Kristanto P, Botteman M, Vo P, Marx S, Lockhart E & Van Hout B (2010) A CONCEPTUAL FRAMEWORK THAT CAPTURES THE MULTIDIMENSIONAL ASPECT OF ADHERENCE IN A HEALTH-ECONOMIC MODEL: AN APPLICATION IN CHRONIC NONMALIGNANT PAIN MANAGEMENT. VALUE HEALTH, Vol. 13(7) (pp A242-A243)
• Thurston S, Webb C, Borgman B & Van Hout B (2010) . VALUE IN HEALTH, Vol. 13(3) (pp A166-A167)
• Thurston S, Webb C, Rejas J & Van Hout B (2010) COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME (ACS) PATIENTS IN SPAIN. VALUE HEALTH, Vol. 13(3) (pp A165-A166)
• Van Hout BA, Botteman M & Dukler A (2010) THE VALUE OF A PREDICTIVE DIAGNOSTIC BLOOD TEST IN MULTIPLE SCLEROSIS (MS). VALUE HEALTH, Vol. 13(3) (pp A137-A137)
• Gu NY, Bell C, Botteman M & Van Hout BA (2010) COMPARING THE TIME TRADEOFF (TTO), THE VISUAL ANALOGUE SCALE (VAS) AND THE EQ-5D VALUE-SETS IN PATIENTS TREATED WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN). VALUE HEALTH, Vol. 13(3) (pp A212-A212)
• Gu NY, Bell C, Botteman M & Van Hout BA (2010) ASSOCIATION BETWEEN SELF-REPORTED NEUROPATHIC PAIN SEVERITY AND THE EQ-5D IN PATIENTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN). VALUE HEALTH, Vol. 13(3) (pp A213-A213)
• Gu NY, Bell C, Botteman M & Van Hout BA (2010) ASSESSING THE IMPACT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN) RELATED HEALTH IMPAIRMENT ON LOSS OF PRODUCTIVE TIME (LOPT). VALUE HEALTH, Vol. 13(3) (pp A61-A61)
• Bojke C, Cifaldi M, Ray S & Van Hout B (2010) MAINTENANCE OF PHYSICAL FUNCTION IMPROVES EMPLOYMENT STATUS OVER TIME FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. RHEUMATOLOGY, Vol. 49 (pp I72-I73)
• Logman F, Heeg B, Botteman M, Kaura S & van Hout B (2009) Economic Evaluation of Zoledronic Acid for the Prevention of Osteoporotic Fractures in Post-Menopausal Women with Early Breast Cancer Receiving Aromatase Inhibitors in the United Kingdom. CANCER RESEARCH, Vol. 69(24) (pp 574S-574S)
• Thurston SJ, Webb K, Ong S, Meerding WJ & van Hout BA (2009) COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE NETHERLANDS. VALUE HEALTH, Vol. 12(7) (pp A335-A335)
• Heeg BMS, Treur MJ & van Hout BA (2009) HANDLING UNCERTAINTY IN THE CASE OF COMBINED END-POINTS. VALUE HEALTH, Vol. 12(7) (pp A235-A235)
• On MMLL, Heeg BMS, De Charro F & van Hout BA (2009) COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS. VALUE HEALTH, Vol. 12(7) (pp A235-A235)
• van Hout BA (2009) THE VALUE OF ADDED LIFE YEARS AS A FUNCTION OF AGE, PROGNOSIS AND QUALITY OF LIFE. VALUE HEALTH, Vol. 12(3) (pp A4-A5)
• van Hout BA (2009) THE POWER OF ASSUMPTIONS. VALUE HEALTH, Vol. 12(3) (pp A34-A34)
• Leen C, Thuresson PO, Hegg B, Vardeva K, Gosden T, Yogaratnam JZ & Van Hout B (2009) Cost-effectiveness of atazanavir compared to lopinavir in treatment-naive HIV-1 patients in Scotland. HIV MED, Vol. 10 (pp 41-42)
• Logman JFS, Treur MJ, Verheggen BG, Heeg BMS, Stephens JM, Haider S, Cappelleri JC, Nathwani D, Tice A & Van Hout BA (2008) ASSESSING ANTIMICROBIAL SUCCESS RATES IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI): A BAYESIAN META-ANALYSIS. VALUE HEALTH, Vol. 11(6) (pp A428-A428)
• Verheggen BG, Heeg BMS, Vos CBJ & Van Hout BA (2008) COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS. VALUE HEALTH, Vol. 11(6) (pp A437-A437)
• Verheggen BG, Treur MJ, Heeg BMS, Botteman MF, Van Hout BA & Trocio JN (2008) ESTIMATING THE QUALITY OF LIFE IMPACTS OF TOLTERODINE AND TAMSULOSIN TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER. VALUE HEALTH, Vol. 11(6) (pp A655-A655)
• Thuresson PO, Heeg B, Neubauer AS, Intorcia M & Van Hout BA (2008) COST EFFECTIVENESS ANALYSIS OF REYATAZ (R) VERSUS KALETRA (R) IN THE TREATMENT OF NAIVE HIV PATIENTS IN ITALY. VALUE HEALTH, Vol. 11(6) (pp A351-A351)
• Thurston SJ, Thompson RP, Ong S & van Hout BA (2008) COST EFFECTIVENESS OF HIGH DOSE ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE UK. VALUE HEALTH, Vol. 11(6) (pp A405-A405)
• Logman JFS, Treur MJ, Verheggen BG, Heeg BMS, Stephens J, Spiesser J, Simoneau D, Haider S, Nathwani D & Van Hout BA (2008) A BAYESIAN META-ANALYSIS OF THE EFFICACY OF SIX ANTIMICROBIAL AGENTS FOR CONFIRMED STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT-TISSUE INFECTIONS (CSSTIS). VALUE HEALTH, Vol. 11(6) (pp A428-A428)
• Treur MJ, Heeg B, Moller HJ, Schmeding A & Van Hout BA (2008) A pharmacoeconomic analysis of schizophrenic patients switching from branded to generic risperidone involving a possible compliance loss. VALUE HEALTH, Vol. 11(3) (pp A118-A118)
• Treur MJ, McCracken F, Heeg B, Joshi AV, Thurston S, Verbeggen B, Marc B, de Charro F & van Hout B (2007) Efficacy of recombinant activated factor VII (rFVlla) vs. activated prothrombin complex concentrate (APCC) in patients with hemophilia with inhibitors: A Bayesian meta-analysis. BLOOD, Vol. 110(11) (pp 59B-59B)
• Van der Steen A, Verheggen BG, Heeg BMS & Van Hout BA (2007) Dealing with competing causes of death, illness and costs: The Disease Elimination Life Table Analysis (DELTA) model. VALUE HEALTH, Vol. 10(6) (pp A454-A454)
• Damen J, Heeg BMS, Lothgren M & Van Hout BA (2007) A pharmacoeconomic analysis of compliance gains on antipsychotic medications. VALUE HEALTH, Vol. 10(6) (pp A294-A294)
• Damen J, Heeg B, Lothgren M & Van Hout BA (2007) The cost effectiveness of paliperidone extended-release OROS in Sweden, Finland, Denmark and Norway. VALUE HEALTH, Vol. 10(6) (pp A294-A295)
• Van der Steen A, Heeg B, De Charro F & Van Hout BA (2007) Spatial interpolation. VALUE HEALTH, Vol. 10(6) (pp A453-A453)
• Treur MJ, McCraken F, Heeg BMS, Joshi AV, Botteman MF, De Charro F & Van Hout BA (2007) Recombinant activated factor VII (RFVIIA)vs. activated prothrombin complex concentrate (APCC) for on-demand treatment of joint bleeds in hemophiliacs with inhibitors: A systematic review and Bayesian meta-regression survival model with time-dependent covariates. VALUE HEALTH, Vol. 10(6) (pp A284-A285)
• Damen J, Heeg BMS, Lothgren M & Van Hout BA (2007) The cost-effectiveness of risperidone long-acting injectable in Sweden. VALUE HEALTH, Vol. 10(6) (pp A293-A294)
• Borkent-Raven BA, Janssen MP, De Wit A, Koedijk FD, Van Hout BA & Van der Poel CL (2007) Costs and effects of HBV-NAT screening in the Netherlands. TRANSFUSION, Vol. 47(3) (pp 266A-266A)
• Borkent-Raven BA, Janssen MP, Van Hout BA & Van der Poel CL (2007) The fate of blood components: Distributions of patients to whom they are transfused, their age and diagnoses. TRANSFUSION, Vol. 47(3) (pp 268A-269A)
• Logman F, Heeg B, Botteman MF, Marfatia AA & Van Hout BA (2007) Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: Application to the United Kingdom. EJC SUPPLEMENTS, Vol. 5(4) (pp 156-156)
• Janssen MP, Van der Poel CL, Schaasberg WP, Bonsel GJ & Van Hout BA (2006) Ten years of blood transfusions: Use, disease and survival. TRANSFUSION, Vol. 46(9) (pp 153A-154A)
• Janssen MP, van der Poel CI, Schaasberg W, Bonsel GJ & Van Hout BA (2006) Ten years of blood transufsions: Use, disease and survival. VOX SANG, Vol. 91 (pp 319-319)
• Botteman MF, Hay JW, Van Hout BA, Curry A, Wong R & Luo MP (2006) Cost effectiveness of adalimumab therapy vs. conventional care in the United Kingdom (UK) patients with active ankylosing spondylitis (AS). ANNALS OF THE RHEUMATIC DISEASES, Vol. 65 (pp 207-208)
• Klok RM, Postma MJ, Van Hout BA & Brouwers JR (2005) All proton pump inhibitors are equivalent for treatment of GERD. CLEV CLIN J MED, Vol. 72(12) (pp 1100-1100)
• Van Hout B (2005) Cost effectiveness of fondaparinux compared with enoxaparin for extended prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery using Dutch estimates of costs. VALUE HEALTH, Vol. 8(6) (pp A116-A116)
• Van Hout B (2005) Cost effectiveness of extended prophylaxis with fondaparinux to prevent venous thromboembolism in patients undergoing hip fracture surgery using UK and Dutch estimates of costs. VALUE HEALTH, Vol. 8(6) (pp A116-A116)
• Heeg B, Buskens E, Ingham M, Caleo S, Rabinowitz J & Van Hout B (2005) A discrete event simulation (DES) model to describe schizophrenia. VALUE HEALTH, Vol. 8(6) (pp A207-A207)
• Cohen DJ, Dulisse B, Ryan JW, de Bruyne B, Van Hout BA & Serruys PW (2005) Cost-effectiveness of PCI with or without drug-eluting stents vs. bypass surgery for treatment of multivessel coronary disease: 1-year results from the ARTS I and ARTS II trials. CIRCULATION, Vol. 112(17) (pp U612-U612)
• Heeg BM, Buskens E, Serra AV, Palha AP, Teixeira JM, Figueira L, Jara J & van Hout B (2004) Costs and effects of Risperdal Consta (TM) in comparison to conventional depot and shortacting atypical formulations in Portugal. VALUE HEALTH, Vol. 7(6) (pp 778-778)
• Heeg BMS, Buskens E & van Hout BA (2004) The costs and effects of clopidogrel in comparison to ASA or placebo for several patient populations in Denmark. VALUE HEALTH, Vol. 7(6) (pp 642-642)
• Verschuuren M, van Hout BA & Bonsel GJ (2004) VIOLATIONS OF THE ADDITIVE ASSUMPTION IN THE STANDARD QALY APPROACH: EXTRA-MAXIMAL TRADE OFFS. QUALITY OF LIFE RESEARCH, Vol. 13(9) (pp 1570-1570)
• Verschuuren M, van Hout BA & Bonsel GJ (2004) MODELING TIME TRADE OFF VALUATIONS: IN SEARCH OF A GOOD FIT. QUALITY OF LIFE RESEARCH, Vol. 13(9) (pp 1499-1499)
• Heeg BM, Emmermann A, Laux G, Moller HJ, Naber D & Van Hout BA (2003) Costs and effects of risperdal Consta (TM) in comparison to conventional depot and short-acting atypical formulations in Germany. VALUE HEALTH, Vol. 6(6) (pp 692-692)
• van Hout BA, Tangelder MJD, Bervoets P & Gabriel S (2003) Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation in the Netherlands. VALUE HEALTH, Vol. 6(6) (pp 667-668)
• Azar A, Hoes A, Arends L, Van den Voorde-Rosenbrand K, Bots M, van Hout B, Lubsen J & Grobbee D (2003) Efficacy of treatment of hypertension: A meta-analysis of 68,000 patients and its implications for current practice. JOURNAL OF HYPERTENSION, Vol. 21 (pp S115-S115)
• Lamfers EJ, Schut A, Hooghoudt TE, Hertzberger DP, Stolwijk PW, Boersma E, Verheugt FWA & Van Hout BA (2003) Cost-effectiveness of prehospital thrombolysis. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 41(6) (pp 524A-524A)
• Van Gestel A, Bakker J, Van Hout B & Veraart C (2002) The costs of severe sepsis - The Netherlands, 2000. VALUE HEALTH, Vol. 5(6) (pp 561-561)
• Van Gestel A, Bakker J, Veraart C & Van Hout B (2002) Incidence of severe sepsis in the Netherlands: A point prevalence survey. VALUE HEALTH, Vol. 5(6) (pp 576-576)
• Heeg BM, van Aalst G, van den Arend IJ, Mehnert A & van Hout B (2002) A discrete events model of long-term outcomes and cost of treatment with long acting risperidone in schizophrenia. VALUE HEALTH, Vol. 5(6) (pp 515-516)
• Heeg BM, van Aalst GD, Mehnert A & van Hout B (2002) Simulating the course of schizophrenia using discrete events modelling. VALUE HEALTH, Vol. 5(6) (pp 524-524)
• Lindeboom WK, van Hout BA, Serruys PWS, Unger F, Taeymans Y, van Nooten G, Pieper M & Maass D (2002) Working status after CABG and stented angioplasty: results from the ARTS study. EUROPEAN HEART JOURNAL, Vol. 23 (pp 260-260)
• van Hout BA, Lindeboom WK, Morice MC, de Jong P, Molnar F, Wijns W, Holubarsch C, Bartorelli A & RAVEL investigators (2002) Cost-effectiveness of the sirolimus eluting Bx-VELOCITY stent: 1-year results. EUROPEAN HEART JOURNAL, Vol. 23 (pp 691-691)
• Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard GR, van Hout B & PROWESS Investigators (2002) Cost-effectiveness of drotrecogin alfa (activated) (Xigris (TM)) in severe sepsis. CRIT CARE MED, Vol. 30(2) (pp 493-493)
• Linde-Zwirble WT, Clermont G, Van Hout B, Ball DE, Basson BR & Angus DC (2001) Increased survivorship with drotrecogin alfa (activated) in the treatment of severe sepsis: The effect on hospital costs. CRIT CARE MED, Vol. 29(12) (pp A1-A1)
• Abizaid A, Costa M, Centemero M, Abizaid A, Legrand VMG, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AGMR , Sousa JE et al (2001) Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: Insights from the arterial revascularization therapy study (ARTS) trial.. AM J CARDIOL, Vol. 88(5A) (pp 4G-4G)
• Sheiban I (2001) . Evidence-based Cardiovascular Medicine, Vol. 5(3) (pp 94-95)
• Lindeboom WK, Van Hout BA, Backx B, Unger F, Sousa JE, Jatene A, Bonnier JJRM, Schoenberger JPAM, Buller N & Bonser R (2000) Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in diabetic patients with multivessel disease. CIRCULATION, Vol. 102(18) (pp 550-550)
• Disco CMC, Lindeboom WK, Serruys PW, Unger F, Legrand V, Limet R, van Herwerden L, Carere R, Lichtenstein S & van Hout BA (2000) Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in patients with multi-vessel disease assessed by age. EUR HEART J, Vol. 21 (pp 478-478)
• Lindeboom WK, Serruys PW, Unger F, Schuler G, Mohr FW, Roose PCH, van Geldrop THR, Morel MAM, Disco CMC & van Hout BA (2000) Quality of life after CABG and stented angioplasty: results from the ARTS study. EUR HEART J, Vol. 21 (pp 221-221)
• De Bruyne B, Serruys PW, Carlier S, van Hout B, van Sonsbeek JM, Gurne O, Pijls NHJ, Ziekenhuis C, Belardl JA, Germonprez JL , Schofield PM et al (1999) Debate II: A randomized comparison of cost-effectiveness of primary versus provisional stenting. CIRCULATION, Vol. 100(18) (pp 790-791)
• Van Os N, Niessen LW, Casparie AF & Van Hout BA (1999) Cost-effectiveness analysis of national clinical guidelines. DIABETES, Vol. 48 (pp A416-A416)
• Serruys PW, Unger F, van Herwerden L, Mohr F, Simon R, Albrechts C, Wijns W, van Hout B, van Es GA, Hugenholtz PG & Morel MA (1998) Arterial revascularisation therapy study: The ARTS study, a randomised trial of bypass-surgery versus stenting in multivessel coronary disease.. CIRCULATION, Vol. 98(17) (pp 498-498)
• Heeschen C, Hamm CW, Goldmann BU, Wohlrath S, van Hout BA & Simoons ML (1998) Cost effectiveness of abciximab in patients with unstable angina according to the troponin T status. CIRCULATION, Vol. 98(17) (pp 358-359)
• van Hout B, Gagnon D & McNulty P (1998) Assessing the probability of economic dominance without data from a head to head trial. MED DECIS MAKING, Vol. 18(4) (pp 489-489)
• van Hout BA, Bowman L, Zelinger DJ & Simoons ML (1998) Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. EUROPEAN HEART JOURNAL, Vol. 19 (pp D59-D66)
• van Hout BA, Cohen DJ, Koens BAH & Serruys PW (1998) Costs and effects of stent implantation versus balloon angioplasty. J AM COLL CARDIOL, Vol. 31(2) (pp 50A-50A)
• DeLaet CEDH, vanHout B, Burger H, Hofman A & Pols HAP (1997) Cost-effectiveness of hip fracture prevention: The later the better?. J BONE MINER RES, Vol. 12 (pp F558-F558)

Reports

• Devlin NJ, Shah KK, Feng Y, Mulhern B & van Hout B (2016) Valuing health-related quality of life: An EQ-5D-5L value set for England
• Ara R, Kearns B, Mukuria C, van Hout B & Brazier JE (2013) Examining productivity losses associated with health related quality of life using patient and general population data.
• ara R, van hout B, Kearns B & Brazier JE (2013) Case-mix methodology for the NHS outcomes framework GP Patient Survey Questionnaire Data

Posters

• Schneider P, van Hout B, Heisen M, Brazier JE & Devlin N (2022) P60 A New Online Tool for Valuing Health States: Eliciting Personal Utility Functions for the EQ-5D-5L.

Working papers

• Devlin NJ, Shah KK, Feng Y, Mulhern B & van Hout B (2018) . Health Economics (United Kingdom), 27, 7-22.

Other

• Piena MA, Kroep S, Simons C, Fenwick E, Harty GT, Wong SL & van Hout BA (2022) . Advances in Therapy, 39(2), 909-909.

Preprints

• Durno N, Zormpas E, Schmid R, Heisen M, Hartl K, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T , Cáceres ASJ et al () , Research Square Platform LLC.
• Hartl K, Durno N, Schmid R, Heisen M, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T, Cáceres ASJ , Mühlbacher A et al () , Research Square Platform LLC.
• Devlin N, Buckingham K, Shah K, Tsuchiya A, Tilling CJ, Wilkinson G & van Hout B () .